Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1465664
This article is part of the Research Topic Exploring Oncolytic Virotherapy in Solid Tumor Treatment View all 6 articles

Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5：a case report and literature review

Provisionally accepted
Qiu Zhao Qiu Zhao Min Xiao Min Xiao *Jian Ma Jian Ma *Xiaoqian Li Xiaoqian Li *Minwei Yang Minwei Yang *Yanzhi Bi Yanzhi Bi *
  • Fourth People's Hospital of Changzhou, Changzhou, China

The final, formatted version of the article will be published soon.

    Advanced metastatic cardia cancer is an intractable malignance with poor prognosis. It is often accompanied by upper digestive tract obstruction, which seriously affects the quality of patients. Therefore, effective relief of eating obstruction is an important goal in the treatment of cardia cancer. Immune checkpoint inhibitors (ICIs) have shown significant efficacy in cardia cancer, but only a small percentage of patients will benifit from them due to immune resistance. Oncolytic viruses have been shown to enhance the efficacy of ICIs by altering the immune microenviroment. This indicates that oncolytic virus has the potential value of overcoming the immune resistance of cardia cancer. Here, we present a case with local recurrent and multiple metastatic cardia cancer accompanied by eating obstruction. After 4 cycles of chemotherapy plus ICI therapy, the patient´s matastases were significant shrink, but the recurrent carida lesion were almost unchanged. Then we implemented exploratory local injection of recombinant human adenovirus type 5(H101) into recurrent cardia lesion by painless gastroscopy. Surprisingly, the cardia lesion shrank significantly, and the eating obstruction was greatly relieved. We also observed a significant increase of infiltrated CD4+T cells in biopsy tissues after H101 treatment. Our study not only conformed the value of oncolytic viruses to reverse ICI resistance in patients with gastric cancer, but also revealed its underlying impact on immune microenviroment.

    Keywords: Cardia cancer, immune checkpoint inhibitors, Recombinant Human Adenovirus Type 5, CD4+ T cell, CD8+ T cell, Immune microenviroment

    Received: 16 Jul 2024; Accepted: 10 Sep 2024.

    Copyright: © 2024 Zhao, Xiao, Ma, Li, Yang and Bi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Min Xiao, Fourth People's Hospital of Changzhou, Changzhou, China
    Jian Ma, Fourth People's Hospital of Changzhou, Changzhou, China
    Xiaoqian Li, Fourth People's Hospital of Changzhou, Changzhou, China
    Minwei Yang, Fourth People's Hospital of Changzhou, Changzhou, China
    Yanzhi Bi, Fourth People's Hospital of Changzhou, Changzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.